greeksoup/ stock research
Stock research / United States / BNTX / Year to 31 December 2022

BioNTech SE (BNTX) annual results, year to 31 December 2022: revenue EUR 17,311 million, from the 20-F

BioNTech SE files a 20-F with the SEC once a year, in euros. In the year to 31 December 2022 it reported revenue of EUR 17,311 million ($18.2 billion at the year's average rate), down 8.8% on the year before. Its profit attributable to shareholders was EUR 9,434 million, down 8.3%, and diluted earnings per share EUR 37.77.

Revenue
EUR 17,311 million
-8.8% on the year
FY2017FY2022
Operating margin
73.0%
80.5% a year earlier
FY2017FY2022
Net income
EUR 9,434 million
-8.3% on the year
FY2017FY2022
Diluted EPS
EUR 37.77
-4.7% on the year
FY2017FY2022

this yearthe year beforeIn euros as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2021 †Dec 2022
Revenue18,97717,311
Cost of sales2,9122,995
Research and development9491,537
Operating profit15,28412,643
Finance costs30518.9
Profit before tax15,04612,954
Income tax4,7543,520
Profit for the year10,2929,434
Profit attributable to shareholders10,2929,434
Filing20-F20-F
EUR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2021 †Dec 2022
Diluted EPS39.6337.77
Basic EPS42.1838.78
Filing20-F20-F

EUR per ordinary share, as filed.

Cash flow

Year toDec 2021 †Dec 2022
Cash from operations89013,577
Purchase of property, plant and equipment128329
Free cash flow76213,248
Cash from investing-566-35.3
Cash from financing94.2-1,419
Depreciation and amortisation75.2123
Dividends paid0.0484
Filing20-F20-F

EUR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2021 †Dec 2022
Funded by
Equity attributable to shareholders11,89420,056
Borrowings, as filed302212
Lease liabilities182210
Other liabilities3,4542,801
Total equity and liabilities15,83123,279
Owned
Property, plant and equipment322609
Goodwill57.861.2
Cash and cash equivalents1,69313,875
Trade and other receivables12,3827,146
Inventories502440
Other assets8741,148
Total assets15,83123,279
Filing20-F20-F

EUR million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2021 †Dec 2022
Operating margin80.5%73.0%
Net margin54.2%54.5%
Free cash flow margin4.0%76.5%
Return on year-end equity86.5%47.0%
Effective tax rate31.6%27.2%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2022, filed 10 March 2025: the filing. The figures are in euros as filed.